Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Тотальное облучение костного мозга и лимфоидной ткани перед донорской трансплантацией и применение циклофосфамида в лечении пациентов с острым миелоидным лейкозом

30 сентября 2026 г. обновлено: City of Hope Medical Center

Пилотное исследование общего облучения костного мозга/лимфоидной ткани (TMLI) перед аллогенной трансплантацией гемопоэтических стволовых клеток (HCT) с последующей посттрансплантационной трансплантацией на основе циклофосфамида в сравнении с профилактикой заболеваний хозяина при остром миелогенном лейкозе в стадии полной ремиссии

This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone marrow and blood, instead of applying radiation to the whole body. Giving total bone marrow and lymphoid irradiation before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving total bone marrow and lymphoid irradiation before donor transplant and cyclophosphamide after transplant may work better at treating acute myeloid leukemia.

Обзор исследования

Статус

Активный, не рекрутирующий

Условия

Вмешательство/лечение

Подробное описание

PRIMARY OBJECTIVE:

I. To evaluate the safety/feasibility of combining a total marrow and lymphoid irradiation (TMLI) transplant conditioning regimen with a post-transplant high dose cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis strategy, through the assessment of: adverse events: type, frequency, severity, attribution, time course, duration and complications: including acute GvHD, infection and delayed neutrophil/platelet engraftment.

SECONDARY OBJECTIVES:

I. To estimate the cumulative incidence (CI) of acute GvHD at 100 days post allogeneic hematopoietic cell transplantation (alloHCT).

II. To estimate the CI of chronic GvHD at 6 months, 1- and 2-years post alloHCT.

III. To estimate GVHD-free relapse-free survival (GRFS) at 1- and 2-years post alloHCT.

IV. To describe the kinetics of immune reconstitution and T cell repertoire in the first year post alloHCT.

V. To estimate overall survival (OS), relapse-free survival (RFS) and CI of relapse, and non-relapse mortality (NRM) at 100 days, 1- and 2-years post alloHCT.

VI. To characterize quality of life using 36-Item Short Form Health Survey (SF-36), Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and M. D. Anderson Symptom Inventory (MDASI) or Pediatric Quality of Life Inventory (PedsQL) at 100 days, 6 months, 1- and 2-years post alloHCT.

VII. To assess bone marrow cellularity from bone marrow samples. VIII. To assess the clonogenic potential of cells from bone marrow samples. IX. To assess stromal damage from bone marrow samples. X. To evaluate cytokines and oxidative stress markers.

OUTLINE: This is a dose-escalation study of TMLI.

Patients undergo TMLI twice daily (BID) on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide intravenously (IV) over 2 hours on days 3 and 4, tacrolimus given by continuous intravenous infusion (CIV) on days 5-90, and filgrastim beginning on day 5 until absolute neutrophil count (ANC) is at least 1,500/mm^3 for 3 consecutive days.

After completion of study treatment, patients are followed for up to 24 months.

Тип исследования

Интервенционный

Регистрация (Действительный)

56

Фаза

  • Фаза 1

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 16 лет до 60 лет (Ребенок, Взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • This study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)
  • Karnofsky performance status (KPS) >= 70%
  • The effects of radiation on the developing fetus are known to be teratogenic; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  • Patients with acute myelogenous leukemia (AML) who are in first or second complete remission
  • All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques; (red cell exchange or plasma exchange)
  • A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
  • Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 70 ml/min as calculated by the Cockcroft-Gault formula
  • A bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease
  • Patients should also have a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
  • Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value
  • All subjects must have the ability to understand and the willingness to sign a written informed consent; signed informed consent form approved by the Institutional Review Board (IRB) is required; the patient, family member, and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting, all pertinent information with respect to risks and benefits to the donor and recipient will be presented; alternative treatment modalities will be discussed
  • The time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days
  • Prior therapy with etoposide and cyclophosphamide is allowed
  • DONOR: donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)

Exclusion Criteria:

  • Patients should not have any uncontrolled illness including ongoing or active or poorly controlled infection
  • Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; maintenance therapy with Food and Drug Administration (FDA)-approved targeted therapies (e.g. tyrosine kinase inhibitors for Philadelphia chromosome [Ph] positive [+] acute lymphoblastic leukemia [ALL], and FLT inhibitors for FLT3+ patients) will be allowed after day 60 disease assessment
  • Prior radiation therapy that would exclude the use of TMLI
  • Relapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously
  • Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
  • Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
  • Patients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollment
  • Patients with other active malignancies are ineligible for this study, other than localized malignancies
  • Patients that are pregnant or breastfeeding
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to, infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.
  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Н/Д
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Treatment (TMLI, cyclophosphamide)

Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.

Correlative studies

Ancillary studies

Другие имена:
  • Оценка качества жизни

Given IV

Другие имена:
  • Цитоксан
  • СТХ
  • (-)-циклофосфамид
  • 2H-1,3,2-оксазафосфорин, 2-[бис(2-хлорэтил)амино]тетрагидро-, 2-оксид, моногидрат
  • Карлоксан
  • Циклофосфамида
  • Циклофосфамид
  • Циклоксал
  • Клафен
  • CP моногидрат
  • CYCLO-ячейка
  • Циклобластин
  • Циклофосфам
  • Циклофосфамида моногидрат
  • Циклофосфамид моногидрат
  • Циклофосфан
  • Циклостин
  • Цитофосфан
  • Фосфазерон
  • Геноксал
  • Генуксал
  • Ледоксина
  • Митоксан
  • Неосар
  • Ревиммун
  • WR-138719

Ancillary studies

Undergo alloHCT

Другие имена:
  • Аллогенная трансплантация гемопоэтических клеток
  • Аллогенная трансплантация стволовых клеток
  • HSC
  • ТГСК
  • Трансплантация стволовых клеток, аллогенная

Administer according to City of Hope standard operating procedures

Другие имена:
  • Г-КСФ
  • r-metHuG-CSF
  • Нейпоген
  • Рекомбинантный метиониловый колониестимулирующий фактор гранулоцитов человека
  • рГ-КСФ
  • Теваграстим

Given CIV

Другие имена:
  • Программа
  • Гекория
  • ФК 506
  • Фуджимицин
  • Протопик

Undergo TMLI

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
1a. Incidence of adverse events
Временное ограничение: Up to 24 months

Assessed using Bearman Scale Regimen-Related Toxicity scale. Scale range: Grade 0-4 (increasing grade reflects increasing severity), where Grade 0-none/did not experience and Grade 4=death.

Up to 24 months
1b. Incidence of adverse events
Временное ограничение: Up to 24 months

Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale. Scale range: Grade 1-5 (increasing grade reflects increasing severity), where Grade 1 reflects a more milder form of the adverse event and Grade 5=death.

Up to 24 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Время восстановления/приживления нейтрофилов и тромбоцитов
Временное ограничение: От 0-го дня до выздоровления или объявления об отсутствии приживления, оценивается до 24 месяцев.
От 0-го дня до выздоровления или объявления об отсутствии приживления, оценивается до 24 месяцев.
Оценка остаточного повреждения костного мозга
Временное ограничение: До 24 месяцев
До 24 месяцев
Цитокины
Временное ограничение: До 24 месяцев
До 24 месяцев
Маркеры окислительного стресса
Временное ограничение: До 24 месяцев
До 24 месяцев
Acute graft versus host disease (GvHD)
Временное ограничение: Day 0 to 100 (120) days post-transplant

Graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999).

Day 0 to 100 (120) days post-transplant
Chronic GVHD
Временное ограничение: From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months

The first day of chronic GvHD onset will be used to calculate cumulative incidence curves, with relapse/death prior to onset considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999).

From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
GvHD-free/relapse-free survival (GRFS)
Временное ограничение: From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months

Will be calculated using the Kaplan-Meier method.

From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
Levels of immune cells
Временное ограничение: Up to 24 months

Will be measured by flow cytometry for cell subsets: a. T-cells.

Up to 24 months
Levels of immune cells
Временное ограничение: Up to 24 months

Will be measured by flow cytometry for cell subsets: b. B-cells.

Up to 24 months
Levels of immune cells
Временное ограничение: Up to 24 months

Will be measured by flow cytometry for cell subsets: c. natural killer (NK) cells.

Up to 24 months
Levels of immune cells
Временное ограничение: Up to 24 months

Will be measured by flow cytometry for cell subsets: d. regulatory T cells (T-regs).

Up to 24 months
Overall survival
Временное ограничение: From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months

Will be calculated using the Kaplan-Meier method.

From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
Relapse-free survival
Временное ограничение: From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months

Will be calculated using the Kaplan-Meier method.

From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
Relapse
Временное ограничение: From start of therapy, assessed up to 24 months

Will be calculated using the competing risk method as described by Gooley et al. (1999).

From start of therapy, assessed up to 24 months
Non-relapse mortality (NRM)
Временное ограничение: From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months

The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. Will be calculated using the Kaplan-Meier method and the competing risk method as described by Gooley et al. (1999).

From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
Quality of life -Questionnaire
Временное ограничение: Up to 24 months

Assessed using a. 36-Item Short Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

The eight sections are:

  • a1. vitality
  • a2. physical functioning
  • a3. bodily pain
  • a4. general health perceptions
  • a5. physical role functioning
  • a6. emotional role functioning
  • a7. social role functioning
  • a8. mental health
Up to 24 months
Quality of life-Function Assessment
Временное ограничение: Up to 24 months

Assessed using b. Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). (FACT-BMT) is a 47-item, valid and reliable measure of five dimensions of quality of life in bone marrow transplant patients. The dimensions collected and assessed are:

  • b1.physical well being
  • b2. Social and family well being
  • b3. Emotional well being
  • b4. Functional well being
  • b5. Additional concerns.
Up to 24 months
Quality of life -Symptom Inventory
Временное ограничение: Up to 24 months

Assessed using c. M. D. Anderson Symptom Inventory (MDASI). MDASI is a multi-symptom patient-reported outcome (PRO) measure for clinical and research use. Use the MDASI to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. The following parameters will be reported:

  • c1a. Pain
  • c1b. Fatigue
  • c1c. Nausea
  • c1d. Disturbed sleep
  • c1e. Distress/feeling upset
  • c1f. Shortness of breath
  • c1g. Difficulty remembering
  • c1h. Lack of appetite
  • c1i. Drowsiness
  • c1j. Dry mouth
  • c1k. Sadness
  • c1l. Vomiting
  • c1m. Numbness/tingling
  • c1n. Walking
  • c1o. Activity
  • c1p. Working (including housework)
  • c1q. Relations with other people
  • c1r. Enjoyment of life
  • c1s. Mood A total of eight quality of life parameters will be reported on each pediatric transplant patient.
  • c2a.Pain and Hurt
  • c2b. Fatigue and Sleep
  • c2c. Nausea
  • c2d. Worry
  • c2e. Nutrition
  • c2f. Thinking
  • c2g. Communication
Up to 24 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Соавторы

Следователи

  • Главный следователь: Anthony S Stein, City of Hope Medical Center

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

19 марта 2018 г.

Первичное завершение (Оцененный)

12 апреля 2027 г.

Завершение исследования (Оцененный)

12 апреля 2027 г.

Даты регистрации исследования

Первый отправленный

22 февраля 2018 г.

Впервые представлено, что соответствует критериям контроля качества

9 марта 2018 г.

Первый опубликованный (Действительный)

16 марта 2018 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

5 октября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

30 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • 17423
  • 17423 (Другой идентификатор: City of Hope Comprehensive Cancer Center)
  • NCI-2018-00177 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Да

продукт, произведенный в США и экспортированный из США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .